Number of pages: 100 | Report Format: PDF | Published date: November 04, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global cell therapy market was pegged at US$ 9.4 billion in 2021 and is expected to witness a CAGR of 10% during the forecast period.
Cell therapy involves implanting cells into patients' bodies to treat certain illnesses. These cells might be autologous, which means they come from the patient's body, or allogeneic, which means they come from another donor. While multipotent cells can also convert into other cell types, their repertoire is less extensive than that of pluripotent cells, which can transform into every type of cell in the body. It is a set form of cell for primary cells. Depending on the type of treatment, different cell types are used. When replacing cells, stem cells or cells produced from stem cells are employed in stem cell treatment, a type of cell therapy.
The market is primarily driven by the increase in cell-based therapy clinical investigations. As a result, there has been a large global investment in research and its clinical application. The existence of public and private financing organisations, which frequently provide funds to support initiatives across multiple stages of clinical trials, can be credited with the rise in the number of ongoing clinical trials.
The global market has been analysed from five perspectives by cell type, therapy type, therapeutic area, end user and region.
Cell Therapy Market by Use Type
Based on use type, the global cell therapy market has been segmented into clinical and research use. The research segment dominated the market during forecast period due to its application for scientific purposes. The segment is expanding as a result of the expanding R&D initiatives. Additionally, major market participants are heavily funding research initiatives. Governmental organisations are working together on research projects involving cells, in addition to market participants. These elements collectively are fueling the segment's expansion.
Cell Therapy Market by Therapy Type
Based on therapy type, the global cell therapy market has been segmented into autologous, and allogenic. The allogeny segment dominates the segment during forecast period and this trend will continue to dominate the during the whole forecast period due to the treatment's capacity to get beyond the drawbacks of the autologous CAR T-cell paradigm, like the difficulties of leukapheresis, and offer effective and widely available CAR therapies.
Cell Therapy Market by Therapeutic Area
Based on therapeutic area, the global cell therapy market has been segmented into malignancies, musculoskeletal disorder, autoimmune disorder, dermatology and other. The autoimmune disorder dominated the segment during forecast period. More than 40% of current treatments use cell therapy as a potential cure for diseases like cancer, autoimmune disorders, and other infectious diseases. The most popular cell therapy in both North America and many Asian countries is hematopoietic stem cell transplantation.
Cell Therapy Market by End User
Based on end user, the global cell therapy market has been segmented into hospital & clinic and academic and research institute. The academic and research institute dominated the segment during forecast period. Stem cells have a large market share in the technological industry and are typically used in research initiatives. The ability to replace, mend, regenerate, or repair damaged tissues, cells, and organs is a significant advantage of cell-based therapies. As an alternative to conventional treatment approaches, researchers are heavily investing in the development of such efficient and secure remedies.
Cell Therapy Market by Region
Based on region, the global cell therapy market has been segmented into North America, Europe, Asia Pacific, Rest of the World. North America is anticipated to have the largest market share. The region's significant market share can be ascribed to the existence of numerous centres and institutes working on stem cell treatment research and development. The Institute for Stem Cell Biology and Regenerative Medicine at Stanford University, the Harvard Stem Cell Institute at Harvard University, the Yale Stem Cell Center, and the Institute for Stem Cell Biology and Regenerative Medicine are among the top eight universities in the world.
Cell treatment is predicted to see a profitable growth rate in Asia Pacific throughout the forecast period. Revenue from the emerging economies of this region is expected to increase as a result of the rising investments made by both innovators and consumers in educating themselves about sophisticated medical therapies. A number of stem cell consortiums exist in Asian nations with the goal of assuring coordinated and targeted R&D initiatives. Due of the accommodating legal systems, patients from western nations are also known to travel to Asia for medical treatment.
Some of the prominent market player in the global cell therapy market include
The global cell therapy market is expected to clock US$ 21.80 billion by 2030.
The global cell therapy market was pegged is expected to witness a CAGR of 10% during the forecast period.
Some of the prominent market player in the global cell therapy market include Kolon TissueGene, Inc., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., Thermo Fisher Scientific Inc., Castle Creek Biosciences, Inc. and others.
The research segment led the global cell therapy market
Cell therapy is a sort of therapy in which a patient receives an injection of live cells to treat a variety of ailments by swapping out unhealthy or defective cells with healthy ones.
*Insights on financial performance is subject to availability of information in public domain